We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

93 hedge funds and large institutions have $276M invested in Dianthus Therapeutics in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 24

0.04% more ownership

Funds ownership: 4% → 4.04% (+0.04%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less funds holding

Funds holding: 97 → 93 (-4)

21% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 19

25% less capital invested

Capital invested by funds: $366M → $276M (-$90.3M)

Holders
93
Holders Change
-4
Holders Change %
-4.12%
% of All Funds
1.63%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
15
Increased
30
Reduced
24
Closed
19
Calls
$86K
Puts
–
Net Calls
+$86K
Net Calls Change
+$85K

Top Buyers

Rank Fund Capital Flow
1
CC
Casdin Capital
New York
+$4.05M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$3.99M
3
WP
Woodline Partners
California
+$3.75M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$3.51M
5
ACM
Aquilo Capital Management
California
+$3.41M

Top Sellers

Rank Fund Capital Flow
1
TGI
TRV GP IV
Massachusetts
-$9.1M
2
EC
EcoR1 Capital
California
-$3.59M
3
GGHC
Gilder Gagnon Howe & Co
New York
-$2.42M
4
O
OrbiMed
New York
-$1.03M
5
Citadel Advisors
Citadel Advisors
Florida
-$1.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
26
Federated Hermes
Pennsylvania
$1.58M -$6.06K -52 -0.4%
EP
27
Eversept Partners
New York
$1.45M +$1.45M +12,430 New
Dimensional Fund Advisors
28
Dimensional Fund Advisors
Texas
$1.4M -$839K -7,204 -38%
Goldman Sachs
29
Goldman Sachs
New York
$1.25M +$136K +1,165 +12%
CS
30
Credit Suisse
Switzerland
$1.14M +$834K +7,159 +274%
Two Sigma Investments
31
Two Sigma Investments
New York
$1.04M -$209K -1,793 -17%
Truist Financial
32
Truist Financial
North Carolina
$916K +$53.1K +456 +6%
N
33
Nuveen
North Carolina
$697K +$9.44K +81 +1%
IHAM
34
Integral Health Asset Management
New York
$655K +$109K +937 +20%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$609K +$31.1K +267 +5%
Charles Schwab
36
Charles Schwab
California
$605K +$60.2K +517 +11%
AA
37
ALPS Advisors
Colorado
$523K +$56.4K +484 +12%
First Trust Advisors
38
First Trust Advisors
Illinois
$382K +$382K +3,279 New
Bank of America
39
Bank of America
North Carolina
$281K +$198K +1,696 +236%
DCM
40
Dupont Capital Management
Delaware
$280K +$89.5K +768 +47%
AQR Capital Management
41
AQR Capital Management
Connecticut
$275K +$275K +2,359 New
AllianceBernstein
42
AllianceBernstein
Tennessee
$261K -$18.2K -156 -7%
FT
43
Fiduciary Trust
Massachusetts
$222K +$4.08K +35 +2%
Wells Fargo
44
Wells Fargo
California
$203K +$199K +1,712 +5,903%
State of Wisconsin Investment Board
45
State of Wisconsin Investment Board
Wisconsin
$191K – – –
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$180K -$14.8K -127 -8%
Renaissance Technologies
47
Renaissance Technologies
New York
$177K +$177K +1,519 New
BFM
48
Boothbay Fund Management
New York
$162K +$75.3K +646 +87%
Barclays
49
Barclays
United Kingdom
$151K -$41.2K -354 -22%
HTC
50
Hershey Trust Company
Pennsylvania
$148K +$148K +1,268 New
1
2
3 4 5

DNTH Hedge Fund Activity: Q3 2021 in Review

93 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q3 2021, worth a combined $276M — down 25% from $366M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of DNTH and 15 opened new positions — a net loss of 4 holders — while 24 trimmed existing stakes and 30 added.

The largest buyer was Casdin Capital, adding an estimated $4.05M. The largest seller was TRV GP IV, cutting an estimated $9.1M.

  • 93 institutional investors held Dianthus Therapeutics (DNTH) as of Q3 2021, down from 97 in Q2 2021.
  • Funds reported $276M of Dianthus Therapeutics stock for Q3 2021, down 25% quarter-over-quarter.
  • 15 funds opened new Dianthus Therapeutics positions in Q3 2021 and 19 closed out, a net change of -4 holders.
  • The largest Dianthus Therapeutics buyer in Q3 2021 was Casdin Capital, an estimated $4.05M added.
  • The largest Dianthus Therapeutics seller in Q3 2021 was TRV GP IV, an estimated $9.1M sold.

Based on aggregated 13F filings for Q3 2021.